Skip to main content
OpenTrials
Completed

NCT Number: NCT03973164

The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma

The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

8 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Affiliated Tumor Hospital，Guangxi Medical University

Nanning, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist.
  • Patients who gave written informed consent were referred for MRI.
  • Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).

Exclusion criteria

  • Pregnancy, general contraindications to MRI.

Treatment and study plan

Primary outcomes

  1. Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis

    Time frame: Within 30 days prior to start of chemotherapy

    MRI-positive lesions that cannot be confirmed by bone marrow cytology and pathology will be confirmed by MRI follow-up.

Secondary outcomes

  1. Agreement Between MRI and 18F-FDG PET/CT at Diagnosis

    Time frame: Within 30 days prior to start of chemotherapy

    Region based agreement (%; kappa value) of MRI with 18F-FDG PET/CT at diagnosis.

Sponsors and collaborators

Lead sponsor

Guangxi Medical University

Other

Registry information

Official study title

Bone Marrow Cytology, Pathology and 18F-FDG PET/CT and Pelvic MRI in the Diagnosis of Lymphoma Bone Marrow Invasion

Acronym: PMRIL

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 4, 2019
Registry last updated
Jun 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.